Navigation Links
Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval
Date:6/19/2013

Blue Earth, MN (PRWEB) June 19, 2013

Express Diagnostics Int’l, Inc., manufacturer of DrugCheck® on-site drugs of abuse tests, today announced that it has received Class III medical device license approval from Health Canada to market and sell its DrugCheck® NxStep Onsite Drug Screen Cup in Canada. Class III licensure allows use of the rapid screening device in near-patient settings, such as physicians’ offices.

The DrugCheck NxStep Onsite Drug Screen Cup received Health Canada Class III approval for 24 different drugs and detection levels, or cutoffs. In addition to tests typically included in drugs of abuse urine screens, such as amphetamine, cocaine, opiates, and marijuana, the Drug Screen Cup is also approved to screen for drugs not often cleared for Health Canada Class III, including cotinine (nicotine), EDDP, K2/spice (synthetic marijuana), ketamine, and alcohol.

“We are very pleased to receive Health Canada Class III licensure for our NxStep Onsite Drug Screen Cup,” says Paul Johnson, CEO of Express Diagnostics. “Canada Class III approval will allow for wider distribution of our U.S.-made DrugCheck product, but more importantly, the expansive list of drugs and cutoffs approved for use in our Drug Screen Cup will deliver greater testing flexibility to administrators and healthcare providers throughout Canada to help improve screening and treatment for employees and patients nationwide.”

While the DrugCheck NxStep Onsite Drug Screen Cup is now Health Canada Class III approved in Canada, the device has been FDA 510(k) cleared-to-market for 17 drugs and detection levels (cutoffs) in the U.S. for several years. FDA 510(k) clearance allows the NxStep Onsite Drug Screen Cup to be used in the U.S. for pre-employment, random, and reasonable cause screening, as well as corrections, clinical, and hospital settings. The additional seven drugs and cutoffs approved by Health Canada for inclusion in the Drug Screen Cup are currently available in the U.S. as forensic use.

The DrugCheck NxStep Onsite Drug Screen Cup rapid test provides results in five minutes and can screen for up to 15 drugs of abuse simultaneously. It combines a collection cup and testing device for rapid results, convenience, and accuracy. The self-contained urinalysis screening cup detects the presence of drug metabolites in minutes, using Substance Abuse and Mental Health Services Administration (SAMHSA) cutoff levels. Simply collect urine into the cup, remove the privacy label, and read the results in five minutes. Presumptive positive results are confirmed at a laboratory.

As an ISO 13485:2003-certified manufacturer, Express Diagnostics met the requirement of Health Canada Medical Devices Regulations that all Class III medical devices be designed and manufactured under ISO standards for medical device manufacturing.

Learn more about the Health Canada Class III approved DrugCheck NxStep Onsite Drug Screen Cup at drugscreencup.com.

About Express Diagnostics Int’l, Inc.
Express Diagnostics Int’l manufactures and distributes DrugCheck® on-site urine and saliva screening devices for the detection of drugs of abuse, as well as a growing catalog of health screening devices. With accuracy comparable to laboratory testing, Express Diagnostics onsite devices provide a variety of industries fast, cost-effective alternatives to higher-priced lab services. Learn more at drugcheck.com.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10843108.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. New Genedata Expressionist for Mass Spectrometry Showcases at 2013 ASMS
2. Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team
3. Ingenuity Systems and Affymetrix Partner to Eliminate Microarray Expression Analysis Bottleneck
4. Express Genes by Eurofins MWG Operon Offers 4 Day Delivery of Synthetic Genes
5. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
6. Ono Pharmaceutical Selects Genedata Expressionist for Mass Spectrometry
7. Eurofins MWG Operon’s Express Oligos Provide Faster Than Ever Service
8. Free Research Report on Dyax Corp., Ebix, Inc., 8x8, Inc., EnerSys and Express Scripts Holding Co.
9. transOMIC technologies Releases Tagged ORF Clones for Protein Expression
10. Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview
11. Exon skipping to restore gene expression is promising therapeutic strategy for muscular dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter type of company ... is accounted to two main factors. The first is the amazing customer service ... supplying FireflySci products all around the world. , 2016 was a tremendous sales year ...
(Date:1/19/2017)... , Jan. 18, 2017 BD (Becton, Dickinson and Company) ... today that it will host a live webcast of its Annual ... (ET). The webcast can be accessed from the ... replay through Tuesday, January 31, 2017. ... About BD BD is a global ...
(Date:1/18/2017)... 18, 2017   Parent Project Muscular Dystrophy (PPMD) ... Duchenne muscular dystrophy (Duchenne) , today announced a ... Institute of Technology (NJIT) and Talem Technologies (Talem) as ... technology to assist people living with Duchenne. PPMD ... – an embedded computer, software, a force sensor and ...
(Date:1/18/2017)... ... 2017 , ... MYOLYN, which creates medical technology for people ... to the FDA, requesting clearance of the MyoCycle Home and the MyoCycle Pro ... , The submission marks a major milestone for the technology startup. MYOLYN spun ...
Breaking Biology Technology:
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... Forecasts, 2015 - 2022," projects that the global biometric technology market is expected to ... 2016 to 2022. Continue Reading ... ...      ...
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/4/2017)... LAS VEGAS , Jan. 4, 2017  For the thousands of ... , a global leader in connected health and biometric measurement devices and ... pressure monitors. On display in A&D Medical,s special CES ... monitors represent the ongoing expansion of the company,s WellnessConnected product ... ...
Breaking Biology News(10 mins):